|69.72||-1.26||-1.78%||Vol 969.35K||1Y Perf -25.46%|
|Aug 11th, 2022 16:00 DELAYED|
|- -||-0.21 -0.30%|
|Target Price||86.46||Analyst Rating||Moderate Buy 2.08|
|Potential %||24.01||Finscreener Ranking||★★★★ 52.74|
|Insiders Trans % 3/6/12 mo.||-100/-95/-98||Value Ranking||★★★+ 52.75|
|Insiders Value % 3/6/12 mo.||-100/-93/-98||Growth Ranking||★★★★+ 61.87|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-93/-97||Income Ranking||— -|
|Price Range Ratio 52W %||35.30||Earnings Rating||Strong Sell|
|Market Cap||4.16B||Earnings Date||2nd Aug 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-2.23|
|EPS Growth Next 5 Years %||34.00|
|Avg. Weekly Volume||970.93K|
|Avg. Monthly Volume||732.70K|
|Avg. Quarterly Volume||780.98K|
Blueprint Medicines Corporation (NASDAQ: BPMC) stock closed at 69.72 per share at the end of the most recent trading day (a -1.78% change compared to the prior day closing price) with a volume of 969.35K shares and market capitalization of 4.16B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 429 people. Blueprint Medicines Corporation CEO is Jeffrey W. Albers.
The one-year performance of Blueprint Medicines Corporation stock is -25.46%, while year-to-date (YTD) performance is -34.91%. BPMC stock has a five-year performance of 51.2%. Its 52-week range is between 43.46 and 117.86, which gives BPMC stock a 52-week price range ratio of 35.30%
Blueprint Medicines Corporation currently has a PE ratio of -4.80, a price-to-book (PB) ratio of 3.62, a price-to-sale (PS) ratio of 16.11, a price to cashflow ratio of 16.20, a PEG ratio of 2.32, a ROA of -48.57%, a ROC of -52.47% and a ROE of -59.03%. The company’s profit margin is 41.08%, its EBITDA margin is -289.80%, and its revenue ttm is $193.94 Million , which makes it $3.26 revenue per share.
Of the last four earnings reports from Blueprint Medicines Corporation, there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-2.23 for the next earnings report. Blueprint Medicines Corporation’s next earnings report date is -.
The consensus rating of Wall Street analysts for Blueprint Medicines Corporation is Moderate Buy (2.08), with a target price of $86.46, which is +24.01% compared to the current price. The earnings rating for Blueprint Medicines Corporation stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Blueprint Medicines Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Blueprint Medicines Corporation has a Buy technical analysis rating based on Technical Indicators (ADX : 8.11, ATR14 : 3.85, CCI20 : 128.48, Chaikin Money Flow : 0.19, MACD : 4.16, Money Flow Index : 61.11, ROC : 37.60, RSI : 54.91, STOCH (14,3) : 90.26, STOCH RSI : 0.81, UO : 70.76, Williams %R : -9.74), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Blueprint Medicines Corporation in the last 12-months were: Ariel Hurley (Option Excercise at a value of $41 076), Ariel Hurley (Sold 7 856 shares of value $666 875 ), Becker Hewes (Option Excercise at a value of $676 178), Becker Hewes (Sold 20 932 shares of value $1 810 348 ), Christina Rossi (Sold 2 244 shares of value $130 986 ), Christopher K. Murray (Sold 6 568 shares of value $406 055 ), Debra Durso-Bumpus (Option Excercise at a value of $182 455), Debra Durso-Bumpus (Sold 8 563 shares of value $827 154 ), Fouad Namouni (Sold 4 288 shares of value $377 032 ), George D. Demetri (Sold 10 shares of value $586 ), Jeffrey W. Albers (Option Excercise at a value of $2 189 040), Jeffrey W. Albers (Sold 235 210 shares of value $19 357 504 ), Kathryn Haviland (Option Excercise at a value of $72 100), Kathryn Haviland (Sold 4 767 shares of value $360 713 ), Mark Alan Goldberg (Buy at a value of $299 900), Michael Landsittel (Sold 2 375 shares of value $138 869 ), Nicholas Lydon (Option Excercise at a value of $213 053), Percy H. Carter (Sold 1 908 shares of value $114 022 ), Tracey McCain (Option Excercise at a value of $992 600), Tracey McCain (Sold 37 714 shares of value $3 919 968 )
Thu, 07 Jul 2022 16:25 GMT Blueprint Medicines (BPMC) Gets a Buy Rating from JMP Securities- TipRanks. All rights reserved.
Tue, 05 Jul 2022 02:05 GMT Blueprint Medicines (BPMC) Gets a Buy Rating from Stifel Nicolaus- TipRanks. All rights reserved.
Mon, 04 Jul 2022 02:49 GMT Blueprint Medicines (BPMC) Gets a Buy Rating from Robert W. Baird- TipRanks. All rights reserved.
Fri, 01 Jul 2022 12:36 GMT Blueprint Medicines (BPMC) Gets a Hold Rating from SVB Securities- TipRanks. All rights reserved.
Fri, 10 Jun 2022 10:15 GMT Analysts Conflicted on These Healthcare Names: Blueprint Medicines (BPMC) and IMARA (IMRA)- TipRanks. All rights reserved.
Mon, 11 Apr 2022 04:20 GMT Blueprint Medicines (BPMC) Receives a Buy from JMP Securities- TipRanks. All rights reserved.
Tue, 15 Feb 2022 09:31 GMT Blueprint Medicines (BPMC) Receives a Buy from Leerink Partners- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.